talimogene laherparepvec在美国临床应用于黑色素瘤的观察研究（COSMUS-1）

IF 1 Q4 ONCOLOGY Melanoma Management Pub Date : 2019-06-01 DOI:10.2217/mmt-2019-0012

M. Perez, J. Zager, T. Amatruda, R. Conry, C. Ariyan, Anupam M. Desai, J. Kirkwood, S. Treichel, D. Cohan, L. Raskin

{"title":"talimogene laherparepvec在美国临床应用于黑色素瘤的观察研究（COSMUS-1）","authors":"M. Perez, J. Zager, T. Amatruda, R. Conry, C. Ariyan, Anupam M. Desai, J. Kirkwood, S. Treichel, D. Cohan, L. Raskin","doi":"10.2217/mmt-2019-0012","DOIUrl":null,"url":null,"abstract":"Aim: Talimogene laherparepvec (T-VEC) is an intralesional treatment for unresectable cutaneous, subcutaneous and nodal melanoma. COSMUS-1 was conducted to examine how T-VEC is used in US clinical practice. Materials & methods: A chart review was conducted at seven centers, with 78 patients screened and 76 eligible. Results: Patients began treatment with T-VEC between October 2015 and December 2016. Median follow-up was 9.4 months. Twenty percent of patients (n = 15) completed T-VEC treatment with no remaining injectable lesions or pathologic complete response. Flu-like symptoms were the most commonly reported adverse events (n = 8; 10.5%), followed by lesion ulceration (n = 4; 5.3%). No herpetic lesions or infections were reported. Conclusion: T-VEC was well tolerated and showed clinical utility.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2019-0012","citationCount":"20","resultStr":"{\"title\":\"Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1)\",\"authors\":\"M. Perez, J. Zager, T. Amatruda, R. Conry, C. Ariyan, Anupam M. Desai, J. Kirkwood, S. Treichel, D. Cohan, L. Raskin\",\"doi\":\"10.2217/mmt-2019-0012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: Talimogene laherparepvec (T-VEC) is an intralesional treatment for unresectable cutaneous, subcutaneous and nodal melanoma. COSMUS-1 was conducted to examine how T-VEC is used in US clinical practice. Materials & methods: A chart review was conducted at seven centers, with 78 patients screened and 76 eligible. Results: Patients began treatment with T-VEC between October 2015 and December 2016. Median follow-up was 9.4 months. Twenty percent of patients (n = 15) completed T-VEC treatment with no remaining injectable lesions or pathologic complete response. Flu-like symptoms were the most commonly reported adverse events (n = 8; 10.5%), followed by lesion ulceration (n = 4; 5.3%). No herpetic lesions or infections were reported. Conclusion: T-VEC was well tolerated and showed clinical utility.\",\"PeriodicalId\":44562,\"journal\":{\"name\":\"Melanoma Management\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2019-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/mmt-2019-0012\",\"citationCount\":\"20\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Melanoma Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/mmt-2019-0012\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Melanoma Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/mmt-2019-0012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 20

摘要

目的：Talimogene laherparepvec（T-VEC）是一种不可切除的皮肤、皮下和淋巴结黑色素瘤的病灶内治疗方法。COSMUS-1旨在研究T-VEC在美国临床实践中的应用。材料和方法：在七个中心进行了图表审查，共有78名患者接受了筛查，76名符合条件。结果：患者于2015年10月至2016年12月开始接受T-VEC治疗。中位随访时间为9.4个月。20%的患者（n=15）完成了T-VEC治疗，没有剩余的可注射病变或病理学完全反应。流感样症状是最常见的不良事件（n=8；10.5%），其次是病变溃疡（n=4；5.3%）。没有疱疹性病变或感染的报告。结论：T-VEC具有良好的耐受性和临床应用价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1)

Aim: Talimogene laherparepvec (T-VEC) is an intralesional treatment for unresectable cutaneous, subcutaneous and nodal melanoma. COSMUS-1 was conducted to examine how T-VEC is used in US clinical practice. Materials & methods: A chart review was conducted at seven centers, with 78 patients screened and 76 eligible. Results: Patients began treatment with T-VEC between October 2015 and December 2016. Median follow-up was 9.4 months. Twenty percent of patients (n = 15) completed T-VEC treatment with no remaining injectable lesions or pathologic complete response. Flu-like symptoms were the most commonly reported adverse events (n = 8; 10.5%), followed by lesion ulceration (n = 4; 5.3%). No herpetic lesions or infections were reported. Conclusion: T-VEC was well tolerated and showed clinical utility.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.